Eli Lilly & Co. (LLY) Issues Encouraging Update on Abemaciclib Phase 1 in Certain Metastatic Breast Cancer
Tweet Send to a Friend
Eli Lilly and Company (NYSE: LLY) announced results from the MONARCH 1 Phase 2 study of abemaciclib, a cyclin-dependent kinase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE